109 filings
Page 3 of 6
8-K
od955q d9by4le
8 Jun 20
Rocket Pharmaceuticals Announces Private Exchange Transaction
7:10am
8-K
7xke45n7jl4ozx
1 May 20
Other Events
12:00am
8-K
pi9at0g ja5iyae
22 Apr 20
Departure of Directors or Certain Officers
4:16pm
8-K
2nocs3j22bvai52w
20 Feb 20
Entry into a Material Definitive Agreement
5:20pm
8-K
fkb44
11 Feb 20
Rocket Pharmaceuticals Announces Private Exchange Transactions Regarding Outstanding Convertible Senior Notes due 2021
5:26pm
8-K
qghg2x36370zn8w
13 Dec 19
Entry into a Material Definitive Agreement
4:02pm
8-K
t5np7n5 kh
31 Oct 19
Departure of Directors or Certain Officers
4:02pm
8-K
mb0iy kfi
19 Jun 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:20pm
8-K
om7rmiutm8 6gh
19 Jun 19
Submission of Matters to a Vote of Security Holders
4:19pm
8-K
r13al
18 Apr 19
Entry into a Material Definitive Agreement
4:03pm
8-K
rs3rust
28 Dec 18
Other Events
5:05pm
8-K
1doebjut
29 Nov 18
Entry into a Material Definitive Agreement
4:01pm
8-K
c3vlss110r9amn2
26 Nov 18
Regulation FD Disclosure
4:16pm
8-K
lxzu0sv
26 Nov 18
Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector
4:02pm
8-K
p7um9tml 608
25 Jun 18
Departure of Directors or Certain Officers
4:35pm
8-K
ma4f9nytfev7vx
18 May 18
Regulation FD Disclosure
4:01pm
8-K
s4w8tal8a 67
4 Apr 18
Departure of Directors or Certain Officers
12:00am
8-K
hgljznt 53l
21 Mar 18
Changes in Registrant's Certifying Accountant
12:00am
8-K
a8fxmuh wywfly
7 Mar 18
Rocket Pharmaceuticals Reports Full Year 2017 Financial Results and Operational Highlights
12:00am
8-K
qmdx5m8xjj7occ46tj
25 Jan 18
Entry into a Material Definitive Agreement
12:00am